ArticleOPEN ACCESS

A glypican-3-derived peptide vaccine against hepatocellular carcinoma

OncoImmunology
DOI: 10.4161/onci.21351
25Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine. © 2012 Landes Bioscience.

Author supplied keywords

Cite

CITATION STYLE

APA

Sawada, Y., Sakai, M., Yoshikawa, T., Ofuji, K., & Nakatsura, T. (2012). A glypican-3-derived peptide vaccine against hepatocellular carcinoma. OncoImmunology. https://doi.org/10.4161/onci.21351

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free